Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, one has given a buy rating and two have issued a strong buy rating on the company.
A number of research analysts have recently issued reports on RHHBY shares. Morgan Stanley began coverage on shares of Roche in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Sanford C. Bernstein raised Roche to a “strong-buy” rating in a report on Thursday, January 30th. Finally, UBS Group upgraded shares of Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th.
Read Our Latest Stock Report on Roche
Hedge Funds Weigh In On Roche
Roche Price Performance
Shares of RHHBY stock opened at $43.25 on Friday. Roche has a fifty-two week low of $29.20 and a fifty-two week high of $43.96. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. The stock has a 50 day simple moving average of $39.81 and a two-hundred day simple moving average of $38.53.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
See Also
- Five stocks we like better than Roche
- 3 REITs to Buy and Hold for the Long Term
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Shanghai Stock Exchange Composite Index?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to invest in marijuana stocks in 7 steps
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.